Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug BMS-986368 for treating post-stroke spasticity in adults who have had a stroke. Post-stroke spasticity affects muscles causing tightness and spasms, impairing upper-limb function and daily activities. Current treatments often provide limited relief and have side effects, so this study aims to find a new therapy option. This Phase 2, randomized, double-blind, placebo-controlled pilot trial will assess the safety, tolerability, and effectiveness of BMS-986368 for this condition. Participants will be randomly assigned to receive either oral BMS-986368 or a placebo. The drug dosage will escalate from 1 mg once daily to 3 mg and then 6 mg once daily during the 8-week double-blind treatment period. Those who finish this period may join an optional 8-week extension where all receive active treatment while still blinded. The study also includes a screening phase lasting up to 4 weeks and a 4-week safety follow-up, totaling about 24 weeks. Throughout the study, participants will undergo assessments including the Tardieu Scale and Upper Limb Fugl-Meyer Assessment to measure spasticity and motor function. Additional evaluations will track symptoms, adverse events, and drug levels. Participants will be monitored for safety and tolerability during treatment and follow-up. The research aims to see if BMS-986368 improves muscle spasticity and upper limb function compared to placebo in adults with post-stroke spasticity.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Corabotase also called IPN10200 for treating adults with upper limb spasticity. This study aims to understand how Corabotase affects the body and to determine which doses provide the best balance of safety and benefit. The trial involves adult participants aged 18 to 70 years who have spastic hemiparesis following stroke or traumatic brain injury and meet other specific health criteria. The study includes several groups receiving different doses of Corabotase, Dysport, or placebo as single injections into various upper limb muscles. Participants are assigned randomly to groups, with some in dose-escalation cohorts and others in fixed-dose groups. The injections are given once, and doses are carefully adjusted to assess safety and response. The trial uses a double-blind design, meaning neither participants nor researchers know who receives which treatment. Participants will be monitored over nine months with regular assessments including physical exams, vital signs, lab tests, and evaluations of muscle spasticity using the Modified Ashworth Scale. Researchers will track any side effects, antibody development, and changes in muscle tone and disability. Patient and physician impressions of treatment effects and pain levels will also be recorded. This long-term follow-up helps researchers understand how the treatments work and their safety over time.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether nightly use of 0.05% atropine eye drops can delay the onset of nearsightedness in children aged 6 to 11 years who are at high risk for developing myopia. This randomized clinical trial compares atropine drops with placebo drops given nightly in both eyes. The study aims to measure the two-year cumulative incidence of myopia and to determine if atropine slows eye growth compared to placebo. Participants receive either 0.05% atropine drops or placebo drops instilled in each eye every night at bedtime. The trial is conducted across multiple centers and includes 606 children randomized to one of the two groups. The study lasts at least two years, during which participants will be monitored to assess the onset of myopia and changes in eye growth. Throughout the trial, participants will have visits every six months for at least two years to evaluate eye measurements using devices like the Myopia Master. Researchers will track the development of myopia and axial elongation of the eye. Safety and adherence to the treatment will be monitored, and the primary outcomes focus on myopia incidence and eye growth over the two-year period.
Actively Recruiting
Researchers are evaluating the Q Therapeutic System BQ 3.0, a wearable medical device that delivers very low-intensity, frequency-tuned electromagnetic fields to stimulate brain networks. This study aims to assess whether this treatment can reduce disability and promote recovery in adults who have experienced an ischemic stroke. The study is conducted across multiple centers and compares active treatment with a sham inactive device in a randomized, double-blind design. The study begins 4 to 21 days after the stroke event. In the first stage up to day 90 post-stroke, participants receive either active or sham treatments five times a week, totaling at least 45 sessions. In the second stage day 90 to day 180, all participants who completed stage 1 can continue to receive active treatments up to five times weekly. In the third stage day 180 to day 270, no treatments are given, and participants are monitored until the final visit. Each session lasts about 60 minutes, including 40 minutes of device use combined with a home-based exercise program. Participants will be trained, with caregiver support as needed, to use the device and perform exercises at home. The study team provides periodic remote supervision and technical support. Assessments of recovery and function will occur at multiple points, including days 45, 90, 180, and 270 after the stroke. Researchers will monitor safety by recording any adverse events or device issues. Usual medical care continues alongside the study treatments throughout the participation period.
Actively Recruiting
Researchers are evaluating GetUp&Go, a program designed to increase physical activity in adults who are at least six months past a moderate-to-severe traumatic brain injury TBI. This randomized controlled trial aims to determine whether participants who start the 10-week GetUp&Go program immediately show greater increases in physical activity and improvements in mental and physical health compared to those placed on a waitlist. The study also explores whether continued use of the programs mobile health app, RehaBot, helps maintain physical activity gains, and examines how individual participant characteristics affect treatment response. The study involves a 10-week intervention where participants receive personalized physical activity plans supported by one-on-one sessions with a therapist twice weekly via videoconference, plus additional check-ins. After this phase, all participants enter a 10-week follow-up where they are randomly assigned to either continue using the RehaBot app without therapist contact or stop using it. Participants on the waitlist initially have no treatment but receive the full program after their wait period. Participants will take part in baseline and follow-up assessments measuring physical activity objectively through accelerometers, and self-reported measures including fatigue, sleep quality, pain, emotional function, and health-related quality of life. Researchers monitor sedentary behavior and moderate-to-vigorous physical activity levels at multiple timepoints to evaluate the programs effects. The total study timeline includes the initial 10-week treatment or waitlist phase and a 10-week follow-up phase, with evaluations after each period.
Actively Recruiting
Researchers are evaluating the effectiveness of the Gloreha Sinfonia4 robotic exoskeleton for upper limb rehabilitation in people who have experienced subacute post-stroke paresis. This international multicenter randomized controlled trial aims to compare robotic-assisted therapy combined with conventional rehabilitation against conventional therapy alone. The main goal is to see if robotic therapy improves voluntary motor control and coordination better, measured by the Fugl-Meyer Assessment for the upper limb motor function. Secondary goals include assessing muscle strength, range of motion, coordination, manual skill, independence in daily activities, patient satisfaction, and any adverse events. Participants are randomly assigned to one of two groups the Experimental Group EG receives robotic-assisted upper limb rehabilitation along with conventional physical and occupational therapy, while the Control Group CG receives only conventional therapy. Both groups undergo 18 sessions, 3 to 5 times per week, with each daily session lasting 90 minutes. The robotic therapy in the EG progresses through passive, assisted, and active mobilization modes over five weeks, with personalized adjustments based on motor ability. Conventional therapy includes tailored motor exercises for shoulder, elbow, wrist, and hand. The study includes a recruitment and treatment phase followed by a 3-month follow-up period. Participants will have clinical assessments at baseline, after treatment around 35 days, and at 3 months follow-up around 125 days. Evaluations include motor function scales, muscle strength, spasticity, pain, dexterity tests, independence measures, and patient satisfaction questionnaires. Follow-up assessments may be conducted in person or by phone using remote scales. Data collection is anonymized and securely stored. Researchers will analyze the clinical and demographic data to understand treatment effects, patient response factors, and rehabilitation outcomes over the 36-month study duration.
Actively Recruiting
Researchers are evaluating whether adding telerehabilitation focused on arm movement to usual care improves arm function and reduces overall disability in adults who have experienced a stroke. This study compares outcomes between participants receiving telerehabilitation plus usual care and those receiving usual care alone. The study targets patients with arm weakness due to stroke occurring 90 to 270 days before enrollment. Participants will be randomly assigned to one of two groups usual care only or usual care plus telerehabilitation. The telerehabilitation involves 36 sessions of activities including exercises, games, and stroke education lasting 70 minutes per day, six days a week for six weeks. Half of these sessions are supervised by a licensed therapist via a secured internet-connected computer, while the other half are done independently. Participants in the usual care group will be offered telerehabilitation after the study concludes. The study lasts about eight months and includes four in-person visits for various assessments such as arm function tests and a brain MRI scan. Researchers will measure changes in arm function using the Action Research Arm Test over two months, along with disability levels using the modified Rankin Scale. Participants will continue their usual care throughout and are monitored for progress and safety during the study.